MeiraGTx Holdings plc Increase (Decrease) in Accounts Payable
MeiraGTx Holdings plc (MGTX) reported Increase (Decrease) in Accounts Payable of $611.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-13
- MeiraGTx Holdings plc increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$7.30M, a 7947.31% decline year-over-year.
- MeiraGTx Holdings plc increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $7.91M.
- MeiraGTx Holdings plc increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$9.95M.
- MeiraGTx Holdings plc increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $606.00K, a 92.75% decline year-over-year.
- MeiraGTx Holdings plc increase (decrease) in accounts payable for fiscal 2025 was -$12.31M, a 214.67% decline from fiscal 2024.
- MeiraGTx Holdings plc increase (decrease) in accounts payable for fiscal 2024 was $10.74M, a 360.86% increase from fiscal 2023.
- MeiraGTx Holdings plc increase (decrease) in accounts payable for fiscal 2023 was $2.33M, a 37.65% decline from fiscal 2022.
- MeiraGTx Holdings plc increase (decrease) in accounts payable for fiscal 2022 was $3.74M, a 72.00% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 3 month as first filed | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 6 month as first filed | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 9 month as first filed | Increase (Decrease) in Accounts Payable 12 month | Increase (Decrease) in Accounts Payable 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$7.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $611.00K 10-Q · filed 2026-08-13 | -$9.34M derived: sum of 3 quarters · filed 2026-08-13 | -$8.73M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $7.91M 10-Q · filed 2026-05-14 | -$2.04M derived: sum of 2 quarters · filed 2026-05-14 | -$1.44M derived: sum of 3 quarters · filed 2026-05-14 | -$1.34M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$9.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$9.35M derived: sum of 2 quarters · filed 2026-03-30 | -$9.25M derived: sum of 3 quarters · filed 2026-08-13 | -$12.31M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $606.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $699.00K derived: sum of 2 quarters · filed 2026-08-13 | -$2.36M 10-Q · filed 2025-11-13 | -$5.65M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $93.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.97M 10-Q · filed 2026-08-13 | -$6.25M derived: sum of 3 quarters · filed 2026-08-13 | $2.10M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$3.06M 10-Q · filed 2026-05-14 | -$6.35M derived: sum of 2 quarters · filed 2026-05-14 | $2.01M derived: sum of 3 quarters · filed 2026-05-14 | $2.48M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | -$3.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.07M derived: sum of 2 quarters · filed 2026-03-30 | $5.54M derived: sum of 3 quarters · filed 2026-03-30 | $10.74M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $8.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $8.83M derived: sum of 2 quarters · filed 2025-11-13 | $14.02M 10-Q · filed 2025-11-13 | $10.96M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $472.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $5.67M 10-Q · filed 2025-08-14 | $2.61M derived: sum of 3 quarters · filed 2025-08-14 | -$5.07M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $5.20M 10-Q · filed 2025-05-13 | $2.13M derived: sum of 2 quarters · filed 2025-05-13 | -$5.54M derived: sum of 3 quarters · filed 2025-05-13 | -$7.11M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | -$3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$10.74M derived: sum of 2 quarters · filed 2025-03-13 | -$12.31M derived: sum of 3 quarters · filed 2025-03-13 | $2.33M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | -$7.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$9.25M derived: sum of 2 quarters · filed 2024-11-13 | $5.39M 10-Q · filed 2024-11-13 | $502.00K derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | -$1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $13.07M 10-Q · filed 2024-08-12 | $8.18M derived: sum of 3 quarters · filed 2024-08-12 | $13.10M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $14.64M 10-Q · filed 2024-05-09 | $9.75M derived: sum of 2 quarters · filed 2024-05-09 | $14.67M derived: sum of 3 quarters · filed 2024-05-09 | $13.77M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | -$4.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $31.00K derived: sum of 2 quarters · filed 2024-03-15 | -$872.00K derived: sum of 3 quarters · filed 2024-03-15 | $3.74M 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | $4.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $4.02M derived: sum of 2 quarters · filed 2023-11-14 | $8.63M 10-Q · filed 2023-11-14 | $18.08M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | -$903.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $3.71M 10-Q · filed 2023-08-10 | $13.15M derived: sum of 3 quarters · filed 2023-08-10 | $14.53M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $4.61M 10-Q · filed 2023-05-11 | $14.06M derived: sum of 2 quarters · filed 2023-05-11 | $15.44M derived: sum of 3 quarters · filed 2023-05-11 | $16.36M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $9.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $10.83M derived: sum of 2 quarters · filed 2023-03-14 | $11.75M derived: sum of 3 quarters · filed 2023-03-14 | $13.35M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | $1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.31M derived: sum of 2 quarters · filed 2022-11-10 | $3.90M 10-Q · filed 2022-11-10 | $4.98M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $926.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.52M 10-Q · filed 2022-08-11 | $3.60M derived: sum of 3 quarters · filed 2022-08-11 | $4.79M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $1.59M 10-Q · filed 2022-05-12 | $2.68M derived: sum of 2 quarters · filed 2022-05-12 | $3.86M derived: sum of 3 quarters · filed 2022-05-12 | -$785.00K derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $2.27M derived: sum of 2 quarters · filed 2022-03-10 | -$2.38M derived: sum of 3 quarters · filed 2022-03-10 | $1.57M 10-K · filed 2022-03-10 | $1.57M 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$3.46M derived: sum of 2 quarters · filed 2021-11-10 | $481.00K 10-Q · filed 2021-11-10 | $480.85K 10-Q · filed 2020-11-05 | -$942.69K derived: sum of 4 quarters · filed 2021-11-10 | |||
| 2020-06-30 | -$4.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$704.00K 10-Q · filed 2021-08-11 | -$704.30K 10-Q · filed 2020-08-06 | -$2.13M derived: sum of 3 quarters · filed 2021-08-11 | -$979.59K derived: sum of 4 quarters · filed 2021-08-11 | |||
| 2020-03-31 | $3.94M 10-Q · filed 2021-05-11 | $3.94M 10-Q · filed 2020-05-07 | $2.52M derived: sum of 2 quarters · filed 2021-05-11 | $3.67M derived: sum of 3 quarters · filed 2021-05-11 | $3.63M derived: sum of 4 quarters · filed 2021-05-11 | |||
| 2019-12-31 | -$1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$275.59K derived: sum of 2 quarters · filed 2021-03-11 | -$313.40K derived: sum of 3 quarters · filed 2021-03-11 | -$8.68K 10-K · filed 2021-03-11 | ||||
| 2019-09-30 | $1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.11M derived: sum of 2 quarters · filed 2020-11-05 | $1.42M 10-Q · filed 2020-11-05 | $1.63M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | -$37.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $266.91K 10-Q · filed 2020-08-06 | $484.72K derived: sum of 3 quarters · filed 2020-08-06 | $561.06K derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | $304.72K 10-Q · filed 2020-05-07 | $522.52K derived: sum of 2 quarters · filed 2020-05-07 | $598.87K derived: sum of 3 quarters · filed 2020-05-07 | -$1.99M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $217.81K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $294.15K derived: sum of 2 quarters · filed 2020-03-11 | -$2.29M derived: sum of 3 quarters · filed 2020-03-11 | -$2.12M 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | $76.34K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$2.51M derived: sum of 2 quarters · filed 2019-11-07 | -$2.34M 10-Q · filed 2019-11-07 | -$1.46M derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2018-06-30 | -$2.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$2.41M 10-Q · filed 2019-08-07 | -$1.54M derived: sum of 3 quarters · filed 2019-08-07 | $668.68K derived: sum of 4 quarters · filed 2019-08-07 | ||||
| 2018-03-31 | $171.04K 10-Q · filed 2019-05-14 | $1.05M derived: sum of 2 quarters · filed 2019-05-14 | $3.25M derived: sum of 3 quarters · filed 2019-05-14 | |||||
| 2017-12-31 | $877.95K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $3.08M derived: sum of 2 quarters · filed 2019-03-26 | $4.73M 10-K · filed 2019-03-26 | |||||
| 2017-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $3.85M 10-Q · filed 2018-11-08 | ||||||
| 2017-06-30 | $1.65M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |